Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1

Punnee Pitisuttithum; Phillip W. Berman; Benjaluck Phonrat; Pravan Suntharasamai; Suwanee Raktham; La Ong Srisuwanvilai; Krit Hirunras; Dwip Kitayaporn; Jaranit Kaewkangwal; Sricharoen Migasena; Haynes W. Sheppard; Elizabeth Li; Marlene Chernow; Michael L. Peterson; Riri Shibata; William L. Heyward; Donald P. Francis

doi:10.1097/01.qai.0000136091.72955.4b

Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1

Punnee Pitisuttithum
, Phillip W. Berman
, Benjaluck Phonrat
, Pravan Suntharasamai
, Suwanee Raktham
, La Ong Srisuwanvilai
, Krit Hirunras
, Dwip Kitayaporn
, Jaranit Kaewkangwal
, Sricharoen Migasena
, Haynes W. Sheppard
, Elizabeth Li
, Marlene Chernow
, Michael L. Peterson
, Riri Shibata
, William L. Heyward
, Donald P. Francis

Department of Clinical Tropical Medicine

VAXGEN
Faculty of Tropical Medicine, Mahidol University
Bangkok Metropolitan Administration
Department of Health Services
Novacea, Inc.
Gilead Sciences Incorporated

Research output: Contribution to journal › Article › peer-review

64 Citations (Scopus)

Abstract

A phase I/II trial of a candidate vaccine to prevent HIV infection was carried out in Bangkok, Thailand, testing AIDSVAX B/E (VaxGen, Inc., Brisbane, CA), a bivalent subunit vaccine prepared by combining recombinant gp120 from a subtype B virus (HIV-1_MN) with gp120 from a subtype E virus (HIV-1_A244) in alum adjuvant. The studies provide human data on the immunogenicity of various dose combination of non-subtype B vaccine antigens. The results suggest that AIDSVAX B/E is safe and immunogenic in humans. The optimal dose for humans in developing countries was 300 μg of each antigen (B and E). Clade E responses were measurably increased by immunizing with gp120 B/E over B alone. Using the B/E combination did not interfere with the response to either clade. Antibodies to AIDSVAX B/E were able to bind to oligomeric gp120 on the surface of cells infected with primary isolates of HIV-1.

Original language	English
Pages (from-to)	1160-1165
Number of pages	6
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	37
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1097/01.qai.0000136091.72955.4b
Publication status	Published - 1 Sept 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

AIDS
B-E subtypes
Bivalent gp120
HIV
Thailand
Vaccines

Access to Document

10.1097/01.qai.0000136091.72955.4b

Cite this

Pitisuttithum, P., Berman, P. W., Phonrat, B., Suntharasamai, P., Raktham, S., Srisuwanvilai, L. O., Hirunras, K., Kitayaporn, D., Kaewkangwal, J., Migasena, S., Sheppard, H. W., Li, E., Chernow, M., Peterson, M. L., Shibata, R., Heyward, W. L., & Francis, D. P. (2004). Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. Journal of Acquired Immune Deficiency Syndromes, 37(SUPPL. 1), 1160-1165. https://doi.org/10.1097/01.qai.0000136091.72955.4b

@article{c621c6dd64b44014914a1b874f7b2e10,

title = "Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1",

abstract = "A phase I/II trial of a candidate vaccine to prevent HIV infection was carried out in Bangkok, Thailand, testing AIDSVAX B/E (VaxGen, Inc., Brisbane, CA), a bivalent subunit vaccine prepared by combining recombinant gp120 from a subtype B virus (HIV-1MN) with gp120 from a subtype E virus (HIV-1A244) in alum adjuvant. The studies provide human data on the immunogenicity of various dose combination of non-subtype B vaccine antigens. The results suggest that AIDSVAX B/E is safe and immunogenic in humans. The optimal dose for humans in developing countries was 300 μg of each antigen (B and E). Clade E responses were measurably increased by immunizing with gp120 B/E over B alone. Using the B/E combination did not interfere with the response to either clade. Antibodies to AIDSVAX B/E were able to bind to oligomeric gp120 on the surface of cells infected with primary isolates of HIV-1.",

keywords = "AIDS, B-E subtypes, Bivalent gp120, HIV, Thailand, Vaccines",

author = "Punnee Pitisuttithum and Berman, \{Phillip W.\} and Benjaluck Phonrat and Pravan Suntharasamai and Suwanee Raktham and Srisuwanvilai, \{La Ong\} and Krit Hirunras and Dwip Kitayaporn and Jaranit Kaewkangwal and Sricharoen Migasena and Sheppard, \{Haynes W.\} and Elizabeth Li and Marlene Chernow and Peterson, \{Michael L.\} and Riri Shibata and Heyward, \{William L.\} and Francis, \{Donald P.\}",

year = "2004",

month = sep,

day = "1",

doi = "10.1097/01.qai.0000136091.72955.4b",

language = "English",

volume = "37",

pages = "1160--1165",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Wolters Kluwer Health",

number = "SUPPL. 1",

}

Pitisuttithum, P, Berman, PW, Phonrat, B, Suntharasamai, P, Raktham, S, Srisuwanvilai, LO, Hirunras, K, Kitayaporn, D, Kaewkangwal, J, Migasena, S, Sheppard, HW, Li, E, Chernow, M, Peterson, ML, Shibata, R, Heyward, WL & Francis, DP 2004, 'Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1', Journal of Acquired Immune Deficiency Syndromes, vol. 37, no. SUPPL. 1, pp. 1160-1165. https://doi.org/10.1097/01.qai.0000136091.72955.4b

TY - JOUR

T1 - Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1

AU - Pitisuttithum, Punnee

AU - Berman, Phillip W.

AU - Phonrat, Benjaluck

AU - Suntharasamai, Pravan

AU - Raktham, Suwanee

AU - Srisuwanvilai, La Ong

AU - Hirunras, Krit

AU - Kitayaporn, Dwip

AU - Kaewkangwal, Jaranit

AU - Migasena, Sricharoen

AU - Sheppard, Haynes W.

AU - Li, Elizabeth

AU - Chernow, Marlene

AU - Peterson, Michael L.

AU - Shibata, Riri

AU - Heyward, William L.

AU - Francis, Donald P.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - A phase I/II trial of a candidate vaccine to prevent HIV infection was carried out in Bangkok, Thailand, testing AIDSVAX B/E (VaxGen, Inc., Brisbane, CA), a bivalent subunit vaccine prepared by combining recombinant gp120 from a subtype B virus (HIV-1MN) with gp120 from a subtype E virus (HIV-1A244) in alum adjuvant. The studies provide human data on the immunogenicity of various dose combination of non-subtype B vaccine antigens. The results suggest that AIDSVAX B/E is safe and immunogenic in humans. The optimal dose for humans in developing countries was 300 μg of each antigen (B and E). Clade E responses were measurably increased by immunizing with gp120 B/E over B alone. Using the B/E combination did not interfere with the response to either clade. Antibodies to AIDSVAX B/E were able to bind to oligomeric gp120 on the surface of cells infected with primary isolates of HIV-1.

AB - A phase I/II trial of a candidate vaccine to prevent HIV infection was carried out in Bangkok, Thailand, testing AIDSVAX B/E (VaxGen, Inc., Brisbane, CA), a bivalent subunit vaccine prepared by combining recombinant gp120 from a subtype B virus (HIV-1MN) with gp120 from a subtype E virus (HIV-1A244) in alum adjuvant. The studies provide human data on the immunogenicity of various dose combination of non-subtype B vaccine antigens. The results suggest that AIDSVAX B/E is safe and immunogenic in humans. The optimal dose for humans in developing countries was 300 μg of each antigen (B and E). Clade E responses were measurably increased by immunizing with gp120 B/E over B alone. Using the B/E combination did not interfere with the response to either clade. Antibodies to AIDSVAX B/E were able to bind to oligomeric gp120 on the surface of cells infected with primary isolates of HIV-1.

KW - AIDS

KW - B-E subtypes

KW - Bivalent gp120

KW - HIV

KW - Thailand

KW - Vaccines

UR - https://www.scopus.com/pages/publications/4444309788

U2 - 10.1097/01.qai.0000136091.72955.4b

DO - 10.1097/01.qai.0000136091.72955.4b

M3 - Article

C2 - 15319676

AN - SCOPUS:4444309788

SN - 1525-4135

VL - 37

SP - 1160

EP - 1165

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

IS - SUPPL. 1

ER -

Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this